Molecular Analysis for Precision Oncology Congress 2022 - 14 to 16 October 2022 Amsterdam, Netherlands
en-GBde-DEes-ESfr-FR

Molecular Analysis for Precision Oncology Congress 2022 - 14 to 16 October 2022 Amsterdam, Netherlands

Location: Amsterdam, Netherlands

Lugano, Switzerland, 29 September 2022 - The Molecular Analysis for Precision Oncology Congress 2022 (MAP) is the yearly appointment where leading experts discuss current and future challenges in the rapidly developing field of precision oncology, with the aim of identifying targetable alterations through molecular profiling, to provide the best possible personalised treatment. The congress will be held in person in Amsterdam, Netherlands, and virtually between 14-16 October.

Programme highlights

  • Addressing the genomic evolution of NSCLC, and real-world data on the efficacy of EGFR tyrosine kinase inhibitors in lung adenocarcinoma

  • Related content: Abstracts 3MO and 12P

  • Moving towards recurrence prediction and (molecular) early detection: new applications and updates on techniques to increase ctDNA test sensitivity

  • Related content: Abstracts 11P, 5MO and 10P

  • Understanding cancer risk: from environmental molecular biology to behavioural lifestyle factors

  • Related content: Session on 16 October 2022, 13:40-15:10 CEST

  • Next-generation sequencing technologies to shape personalised risk predictions and cancer profiling

  • Related content: Session on 14 October 2022, 14:00-17:00 CEST

  • New updates on how to interpretate immunoediting signals by stage in lung cancer

  • Related content: Abstract 2MO

Keynote lectures

The results of more than 140 studies from various parts of the world will be presented and published online as a supplement to Annals of Oncology. The abstract titles can be viewed through the online programme.

Media registration
The MAP organisers welcome media interested in obtaining information and reporting on cancer issues. Registration is free to bona fide journalists on presentation of a letter of assignment and a valid press card. Media representatives are required to observe and abide by the Media Policy. To apply for media accreditation, please fill out the form available here.

Further information
MAP Press Office
press@esmo.org

MAP is a joint initiative of Cancer Research UK (CRUK), Unicancer and the European Society for Medical Oncology (ESMO).

Regions: Europe, Switzerland, Netherlands
Keywords: Business, Medical & pharmaceutical, Health, Medical, Public Dialogue - health

Testimonials

For well over a decade, in my capacity as a researcher, broadcaster, and producer, I have relied heavily on Alphagalileo.
All of my work trips have been planned around stories that I've found on this site.
The under embargo section allows us to plan ahead and the news releases enable us to find key experts.
Going through the tailored daily updates is the best way to start the day. It's such a critical service for me and many of my colleagues.
Koula Bouloukos, Senior manager, Editorial & Production Underknown
We have used AlphaGalileo since its foundation but frankly we need it more than ever now to ensure our research news is heard across Europe, Asia and North America. As one of the UK’s leading research universities we want to continue to work with other outstanding researchers in Europe. AlphaGalileo helps us to continue to bring our research story to them and the rest of the world.
Peter Dunn, Director of Press and Media Relations at the University of Warwick
AlphaGalileo has helped us more than double our reach at SciDev.Net. The service has enabled our journalists around the world to reach the mainstream media with articles about the impact of science on people in low- and middle-income countries, leading to big increases in the number of SciDev.Net articles that have been republished.
Ben Deighton, SciDevNet

We Work Closely With...


  • BBC
  • The Times
  • National Geographic
  • The University of Edinburgh
  • University of Cambridge
Copyright 2022 by AlphaGalileo Terms Of Use Privacy Statement